Phase 3 Clinical Trials With Primary Completion Dates in January 2019

This is a list of Phase 3 trials with primary completion dates in January 2019 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
AXSMAxsome Therapeutics, Inc.2019-01-01Phase 3NCT02741791A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder
AXSMAxsome Therapeutics, Inc.2019-01-01Phase 3NCT02504008CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1
CANFCan-Fite Biopharma Ltd2019-01-01Phase 3NCT02647762CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis
EYENEyenovia, Inc.2019-01-01Phase 3NCT03751631Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation
EYENEyenovia, Inc.2019-01-01Phase 3NCT03751098Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation
GKOSGlaukos Corporation2019-01-01Phase 3NCT01461278Multicenter Investigation of the Glaukos® Suprachoroidal Stent Model G3 In Conjunction With Cataract Surgery
JAZZJazz Pharmaceuticals plc2019-01-01Phase 3NCT03030599A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy
LIVNLivaNova PLC2019-01-01Phase 3NCT03279484Safety and Electrical Performances Evaluation of Navigo Leads Equipped With IS4 Connector
MNKMallinckrodt plc2019-01-01Phase 3NCT02321319Open-Label Safety and PK Study of ER Hydromorphone Tablets in Opioid-Tolerant Pediatric Chronic Pain Patients
OSMTOsmotica Pharmaceuticals plc2019-01-01Phase 3NCT03290131A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS
PCRXPacira Pharmaceuticals, Inc.2019-01-01Phase 3NCT02740114Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway
RAREUltragenyx Pharmaceutical Inc.2019-01-01Phase 3NCT02432144A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7
RAREUltragenyx Pharmaceutical Inc.2019-01-01Phase 3NCT03581591Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets